Röllig, C., & Krämer, A. (2018). Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients. Annals of oncology, 29(4), . https://doi.org/10.1093/annonc/mdy030
Chicago Style (17th ed.) CitationRöllig, Christoph, and Alwin Krämer. "Intermediate-dose Cytarabine Plus Mitoxantrone Versus Standard-dose Cytarabine Plus Daunorubicin for Acute Myeloid Leukemia in Elderly Patients." Annals of Oncology 29, no. 4 (2018). https://doi.org/10.1093/annonc/mdy030.
MLA (9th ed.) CitationRöllig, Christoph, and Alwin Krämer. "Intermediate-dose Cytarabine Plus Mitoxantrone Versus Standard-dose Cytarabine Plus Daunorubicin for Acute Myeloid Leukemia in Elderly Patients." Annals of Oncology, vol. 29, no. 4, 2018, https://doi.org/10.1093/annonc/mdy030.